130 related articles for article (PubMed ID: 31106345)
1. Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis.
Yuste JR; Serrano-Alonso M; Carmona-Torre F; Del Pozo JL; Herrero JI
J Antimicrob Chemother; 2019 Sep; 74(9):2817-2819. PubMed ID: 31106345
[No Abstract] [Full Text] [Related]
2. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.
Yuste JR; Bertó J; Del Pozo JL; Leiva J
J Antimicrob Chemother; 2017 Feb; 72(2):625-628. PubMed ID: 27999019
[No Abstract] [Full Text] [Related]
3. Pulmonary nocardiosis treated with tedizolid.
Giménez-Arufe V; Gutiérrez-Urbón JM; Blanco-Aparicio M; Míguez-Rey E; Martín-Herranz MI
Farm Hosp; 2019 Nov; 43(6):208-210. PubMed ID: 31705645
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
[TBL] [Abstract][Full Text] [Related]
5. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
[TBL] [Abstract][Full Text] [Related]
6. Tedizolid: a service evaluation in a large UK teaching hospital.
York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
[TBL] [Abstract][Full Text] [Related]
7. Tedizolid: a new oxazolidinone antimicrobial.
Kisgen JJ; Mansour H; Unger NR; Childs LM
Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
[TBL] [Abstract][Full Text] [Related]
8. The role of tedizolid in skin and soft tissue infections.
Bouza E; Muñoz P; Burillo A
Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119
[TBL] [Abstract][Full Text] [Related]
9. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
[TBL] [Abstract][Full Text] [Related]
10. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.
Ferrández O; Urbina O; Grau S
Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508
[TBL] [Abstract][Full Text] [Related]
11. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.
Cattaneo D; Alffenaar JW; Neely M
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia with Tedizolid and Linezolid.
Lee EY; Caffrey AR
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
[TBL] [Abstract][Full Text] [Related]
13. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
[TBL] [Abstract][Full Text] [Related]
14. tedizolid (SIVEXTRO*) in skin and soft-tissue infections.
Prescrire Int; 2017 Mar; 26(180):63-64. PubMed ID: 30730618
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of long-term use of tedizolid in disseminated nocardiosis after heart transplantation.
Sogbe M; Di Frisco M; Del Pozo JL
Transpl Infect Dis; 2024 Feb; 26(1):e14174. PubMed ID: 37846883
[No Abstract] [Full Text] [Related]
16. Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
Kanafani ZA; Corey GR
Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2019 Apr; 74(4):970-977. PubMed ID: 30561650
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of tedizolid for the treatment of MRSA infections.
Hall RG; Smith WJ; Putnam WC; Pass SE
Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
Betts JW; Abdul Momin HF; Phee LM; Wareham DW
J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
